| Ident. | Authors (with country if any) | Title |
|---|
| 000252 |
J. P. Azulay [France] | Évaluation d'un effet disease modifier dans la maladie de Parkinson : quel schéma d'étude? : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000266 |
P. Cesaro [France] | Maladie de Parkinson : les enjeux du traitement : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ? |
| 000844 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten-Year Follow-Up of Parkinson's Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa |
| 000978 |
Stéphane Thobois [France] | Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature |
| 000A14 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
| 000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000C14 |
Paula Ravenscroft [Royaume-Uni] ; Sylvie Chalon [France] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] | Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia |
| 000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000D49 |
Roberto Maggio [Italie] ; Marco Scarselli [Italie] ; Francesca Novi [Italie] ; Mark J. Millan [France] ; Giovanni U. Corsini [Italie] | Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole |
| 000D54 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000D57 |
Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France] | Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole |
| 000D73 |
Asteria Luzardo-Alvarez [Espagne] ; M. Begona Delgado-Charro [France] ; José Blanco-Mendez [Espagne] | In vivo lontophoretic administration of ropinirole hydrochloride |
| 000F26 |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in Parkinsonian rats |
| 000F48 |
A. D. Korczyn [Israël] ; C. Thalamas [France] ; C. H. Adler [États-Unis] | Dosing with ropinirole in a clinical setting |
| 000F63 |
C. Lebrun-Frenay [France] ; M. Borg [France] | Choosing the right dopamine agonist for patients with Parkinson's disease |
| 000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
| 001053 |
Asteria Luzardo-Alvarez [Espagne] ; M. Begona Delgado-Charro [France, Suisse] ; José Blanco-Mendez [Espagne] | Iontophoretic delivery of ropinirole hydrochloride: Effect of current density and vehicle formulation |
| 001242 |
D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
| 001248 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 001329 |
C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France] | Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease |
| 001416 |
A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie] | The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease |
| 001421 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001454 |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001469 |
D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni] | A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease |
| 001636 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
